U.S. F. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a coll

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10562512		
Filing Date		2005-12-28		
First Named Inventor Ben H		lankamer		
Art Unit		1645		
Examiner Name Not y		el assigned		
Attorney Docket Number		012930-000026		

					U.S.	PATENTS			Remove	
Examiner Cite Initial* Patent Number		Kind Code <sup>1</sup>			Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1									
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove	
Examiner Cite   Publication Number   Kind   Publication   Name of Patenti of cited Docume		entee or Applicant ment	Releva	Columns,Lines whe int Passages or Rele s Appear						
	1								Add	
ir you wisi	n to ac	dd additional U.S. Publi				ENT DOCUM		a button	Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	,	Kind Code <sup>4</sup>	Publication	Name of Patente Applicant of cited Document	or ,	Pages,Columns,Line where Relevant Passages or Relevant Figures Appear	TE
	1									
If you wisi	h to a	d additional Foreign Pa	atent Do	cument	citation	information pl	lease click the Add	button	Add	1
			NON	I-PATEN	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, dily andror country where published.						Тs				

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10562512		
Filing Date		2005-12-28		
First Named Inventor Ben H		lankamer		
Art Unit		1645		
Examiner Name Not yo		et assigned		
Attorney Docket Number		012930-000026		

1	NLITMANS et al., "Assembly of Cytochrome-c Oxidase in Cultured Human Cells," Eur. J. Biochem, Vol 254, (1998) pp. 389-394.	
2	NURANI et al., "Homologous and Heterologous Protein Import into Mitochondria Isolated from the Green Alga Chlamydomonas Renhardti," Plant Molecular Biology, Vol. 35, (1997) pp. 973-960.	
3	PETIT et al., "Climate and Atmospheric History of the Past 420,000 Years from the Vostok loe Core, Antarctica," Nature, Vol. 399, (3 June 1999) pp. 429-436.	
4	PFANNSCHMIDT et al., "Photosynthetic Control of Chloroplast Gene Expression," Nature, Vol. 397, (18 February 1999) pp. 625-628.	
5	POLOSA et al., "Ctoning and Characterisation of mIDBP, a DNA-Binding Protein Which Brids Two Distinct Regions of Sea Urchin Mitochondrial DNA," Nucleic Acids Research, Vol. 27, No. 8, (1999) pp. 1890–1899.	
6	PURTON et al., "Characterisation of the ARGT Gene of Chiamydomonas Reinhardti and its Application to Nuclear Transformation," Eur. J. of Physiol., Vol. 30, (1995) pp. 141-148.	
7	RASMUSSON et al., "Physiological, Blochemical and Molecular Aspects of Mitochondrial Complex I in Plants," Brothimica et Biophysica Acta, Vol. 1844, (1998) pp. 101-111.	
8	REBEILLE et al., *Interaction Between Chloroplasts and Mitochondria in Microsigae, *Plant Physiol., Vol. 88, (1968) pp. 973-975.	
9	RINT/AMAKI et al., "Cooperative Regulation of Light-Harvesting Complex II Phosphorylation via the Plastoquinol and Ferredown-Thioredown System in Chloroplasts," PNAS, Vol. 97, No. 21, (October 10, 2000) pp. 11644-11649.	
10	ROBERTI et al., "DmTTF, A Novel Mitochondrial Transcription Termination Factor that Recognises Two Sequences of Drosophila Melanogaster Mitochondrial DNA," Nucleic Acids Research, Vol. 31, No. 6, (2003) pp. 1597-1604.	
11	SCHONFELD et al., "The Nucleus-Encoded Protein MOC1 is Essential for Mitochondrial Light Acclimation in Chiamydomonas Reinhardtii," The Journal of Biological Chemistry, Vol. 279, No. 48, (November 26, 2004) pp. 5036	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10562512		
Filing Date		2005-12-28		
First Named Inventor Ben F		lankamer		
Art Unit		1645		
Examiner Name Not yo		et assigned		
Attornou Docket Number		012930-000026		

12	SELWOOD et al., "Does the Mitochondrial Transcription-Termination Complex Play an Essential Role in Controlling Differential Transcription of Mitochondrial DNA?" Biochemical Scoety Transcriptions, Vol. 28, Pt. 2, (2000) pp. 154-159.	
13	STEPHENSON et al., "Hydrogenase: A Baclerial Enzyme Activating Molecular Hydrogen," Biochem, Vol. XXV, (1931) pp. 205-214.	
14	STRAUSS et al., "Ligation-Mediated Suppression-PCR as a Powerful Tool to Analyse Nuclear Gene Sequences in the Green Alga Chlamydomonas Renhardti," Photosynthesis Research, Vol. 70, (2001) pp. 311-320.	
15	SVENSSON et al., "Light-Dependent Gene Expression for Proteins in the Respiratory Chain of Potato Leaves," The Plant Journal, Vol. 28, No. 1, (2001) pp. 73-82.	
16	TAM et al., "Cloning of Flagellar Genes in Chlamydomonas Reinhardii by DNA Insertional Mutagenesis," Genetics, Vol. 135, (October 1993) pp. 375-384.	
17	THOMAS et al., "Extinction Risk from Climate Change," Nature, Vol. 427, (8 January 2004) pp. 145-148.	
18	TREBST, "Inhibitors in Electron Flow: Tools for the Functional and Structural Localization of Carmers and Energy Conservation Sites," Methods in Enzymology, Vol. 69, (1980) pp. 675-715.	
19	VENER et al., "Plastocuriol at the Quinol Oxidation Site of Reduced Cytlochrome M Mediatric Signal Transduction Between Light and Protein Phosphorylation: Thylakoid Protein Kinase Deactivation by a Single-Turnover Flash," PNAS, Vol. 94, (1997) pp. 1585-1590.	
20	VENER et al., "A Cyclophilin-Regulated PP2A-Like Protein Phosphatase in Thylakoid Membranes of Plant Chloroplasts," Bochemistry, Vol. 38, (1999) pp. 14955-14965.	
21	VERMA et al., "Differential Regulation of High Light Tolerance in the Mutant and Wild-Type Anacystis Cells," Current Microbiology, Vol. 30, (1995) pp. 373-379.	
22	WOLLMAN, "State Transitions Reveal the Dynamics and Flexibility of the Photosynthetic Apparatus," The EMBO Journal, Vol. 20, No. 14, (2001) pp. 3623-3630.	

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit Zeamingt Name

Application Number		10562512		
iling Date		2005-12-28		
irst Named Inventor Ben H		lankamer		
Art Unit		1645		
Examiner Name Not yo		et assigned		
Attorney Docket Number		012930-000026		

	23	ZERGES et al., "Low Density Membranes are Associated with RNA-Binding Proteins and Thylakoids in the Chloroplast of Chlamydomonas Reinhardtli," The Journal of Cell Biology, Vol. 140, No. 1, (January 12, 1998) pp. 101-110.	
	24	ZITO et al., "The QC Site of Cytochrome b6f Complexes Controls the Activation of the LHOI Kinase," The EMBO Journal, Vol. 18, No. 11, (1999) pp. 2961-2969.	
If you wish	to a	dd additional non-patent literature document citation information please click the Add button Add	

If you wish to add additional non-patent literature document citation information please click the Add button Add

FYAMINER SIGNATURE

Examiner Signature Date Considered

A

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1see Kint Code of USPTO Petert Documents at swer\_USETO\_GOL/ or MPEP 901.04. 2 Enter office that issued the document, by the two-letter of the peter of the peter

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10562512	
	Filing Date		2005-12-28	
First Named Inventor Ben H		Ben H	lankamer	
	Art Unit		1645	
	Examiner Name Not ye		et assigned	
	Attorney Docket Numb	er	012930-000026	

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 97.0F4.137(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c)

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

V Nor

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Jennifer L. Skord/	Date (YYYY-MM-DD)	2007-03-01
Name/Print	Jennifer I. Skord	Registration Number	30.687

This collection of information is required by 3T CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12.9 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary (Tifice, U.S. perpartment of Commence, P. 0. Box 1450, Alexandria, V.S.2311-1450, D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA.22311-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.